These agents provide a measurable outcome advantage compared to other therapeutic options, including chemotherapy and immunotherapy—with the longest median OS of 7 years in patients with ALK-mutated metastatic NSCLC, an achievement unmatched by any other therapeutic option [77]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.